TABLE 4.
AEs in DEL patients receiving ZR‐CHOP.
| AEs | Patients with events, No. (%) | |
|---|---|---|
| All grades | Grade 3–4 | |
| Fever | 12 (25.0) | 0 |
| Febrile neutropenia | 3 (6.3) | 3 (6.3) |
| Gastritis | 1 (2.1) | 0 |
| GERD | 6 (12.5) | 0 |
| Dyspepsia | 9 (18.8) | 0 |
| Oral mucositis | 9 (18.8) | 0 |
| Edema of the limbs | 2 (4.2) | 0 |
| Fatigue | 19 (39.6) | 0 |
| Pulmonary infection | 16 (33.3) | 11 (22.9) |
| Upper respiratory tract infection | 2 (4.2) | 0 |
| Skin Infection | 2 (4.2) | 0 |
| Increased alanine aminotransferase | 11 (22.9) | 0 |
| Increased aspartate transferase | 7 (14.6) | 0 |
| Anemia | 25 (52.1) | 4 (8.3) |
| Neutropenia | 34 (70.8) | 18 (37.5) |
| Thrombocytopenia | 11 (22.9) | 4 (8.3) |
Abbreviations: AEs, adverse events; DEL, double‐expressor lymphoma; GERD, gastroesophageal reflux; ZR‐CHOP, zanubrutinib in combination with R‐CHOP.